176 related articles for article (PubMed ID: 38062103)
1. The myeloma microenvironment and response to immunotherapy.
Danovi S
Nat Genet; 2023 Dec; 55(12):2018. PubMed ID: 38062103
[No Abstract] [Full Text] [Related]
2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies to enhance immune response induced by multiple myeloma cells.
Liu Z; Yang C; Liu X; Xu X; Zhao X; Fu R
Front Immunol; 2023; 14():1169541. PubMed ID: 37275861
[TBL] [Abstract][Full Text] [Related]
5. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.
Swamydas M; Murphy EV; Ignatz-Hoover JJ; Malek E; Driscoll JJ
J Hematol Oncol; 2022 Feb; 15(1):17. PubMed ID: 35172851
[TBL] [Abstract][Full Text] [Related]
6. Advances in immunotherapy in multiple myeloma.
Boussi L; Niesvizky R
Curr Opin Oncol; 2017 Nov; 29(6):460-466. PubMed ID: 28877078
[TBL] [Abstract][Full Text] [Related]
7. Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy.
Yao H; Cheng L; Chen D; Zhang Q; Qiu L; Ren SH; Dou BT; Wang H; Huang J; Fan FY
Expert Rev Anticancer Ther; 2023; 23(8):807-815. PubMed ID: 37343305
[TBL] [Abstract][Full Text] [Related]
8. Cellular Immunotherapy for Multiple Myeloma.
Rosenblatt J; Avigan D
Cancer J; 2019; 25(1):38-44. PubMed ID: 30694858
[TBL] [Abstract][Full Text] [Related]
9. Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance.
Holthof LC; Mutis T
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32316450
[TBL] [Abstract][Full Text] [Related]
10. BSA-AIE Nanoparticles with Boosted ROS Generation for Immunogenic Cell Death Immunotherapy of Multiple Myeloma.
Liu Z; Zhang J; Liu H; Shen H; Meng N; Qi X; Ding K; Song J; Fu R; Ding D; Feng G
Adv Mater; 2023 Feb; 35(7):e2208692. PubMed ID: 36529696
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy strategies in multiple myeloma.
Bae J; Munshi NC; Anderson KC
Hematol Oncol Clin North Am; 2014 Oct; 28(5):927-43. PubMed ID: 25212890
[TBL] [Abstract][Full Text] [Related]
12. Facts and Hopes in Multiple Myeloma Immunotherapy.
Sperling AS; Anderson KC
Clin Cancer Res; 2021 Aug; 27(16):4468-4477. PubMed ID: 33771856
[TBL] [Abstract][Full Text] [Related]
13. Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma.
Lv J; Sun H; Gong L; Wei X; He Y; Yu Z; Liu L; Yi S; Sui W; Xu Y; Deng S; An G; Yao Z; Qiu L; Hao M
Front Immunol; 2022; 13():1077768. PubMed ID: 36532059
[TBL] [Abstract][Full Text] [Related]
14. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.
Lewinsky H; Gunes EG; David K; Radomir L; Kramer MP; Pellegrino B; Perpinial M; Chen J; He TF; Mansour AG; Teng KY; Bhattacharya S; Caserta E; Troadec E; Lee P; Feng M; Keats J; Krishnan A; Rosenzweig M; Yu J; Caligiuri MA; Cohen Y; Shevetz O; Becker-Herman S; Pichiorri F; Rosen S; Shachar I
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33465053
[TBL] [Abstract][Full Text] [Related]
15. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy.
Russell BM; Avigan DE
Int J Hematol; 2023 May; 117(5):652-659. PubMed ID: 36964840
[TBL] [Abstract][Full Text] [Related]
16. The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
Lopes R; Caetano J; Ferreira B; Barahona F; Carneiro EA; João C
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562441
[TBL] [Abstract][Full Text] [Related]
17. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
Kuroda J; Nagoshi H; Shimura Y; Taniwaki M
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1081-8. PubMed ID: 24053207
[TBL] [Abstract][Full Text] [Related]
18. Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer.
Morse W; Nawaz H; Choudhry AA
J Egypt Natl Canc Inst; 2023 Jan; 34(1):58. PubMed ID: 36588130
[TBL] [Abstract][Full Text] [Related]
19. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.
Rotolo A; Caputo V; Karadimitris A
Br J Haematol; 2016 May; 173(3):350-64. PubMed ID: 26953076
[TBL] [Abstract][Full Text] [Related]
20. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.
de Haart SJ; van de Donk NW; Minnema MC; Huang JH; Aarts-Riemens T; Bovenschen N; Yuan H; Groen RW; McMillin DW; Jakubikova J; Lokhorst HM; Martens AC; Mitsiades CS; Mutis T
Clin Cancer Res; 2013 Oct; 19(20):5591-601. PubMed ID: 24004671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
